Trial
NCT03121586
Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
ACADIA Pharmaceuticals Inc.
Collaborators
—
Condition
Schizophrenia
Intervention
Pimavanserin
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-08-24